Lavipharm (LAVI) Stock Overview
Engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 1/6 |
LAVI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Lavipharm S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.98 |
| 52 Week High | €1.00 |
| 52 Week Low | €0.65 |
| Beta | 0.63 |
| 1 Month Change | 19.83% |
| 3 Month Change | 21.91% |
| 1 Year Change | 21.01% |
| 3 Year Change | 155.84% |
| 5 Year Change | -27.04% |
| Change since IPO | -87.57% |
Recent News & Updates
Lavipharm (ATH:LAVI) Takes On Some Risk With Its Use Of Debt
Dec 18
We Think Shareholders Should Be Aware Of Some Factors Beyond Lavipharm's (ATH:LAVI) Profit
Apr 10Recent updates
Lavipharm (ATH:LAVI) Takes On Some Risk With Its Use Of Debt
Dec 18We Think Shareholders Should Be Aware Of Some Factors Beyond Lavipharm's (ATH:LAVI) Profit
Apr 10Lavipharm's (ATH:LAVI) Earnings Aren't As Good As They Appear
Sep 26Some Shareholders Feeling Restless Over Lavipharm S.A.'s (ATH:LAVI) P/E Ratio
Aug 06Here's Why Lavipharm (ATH:LAVI) Has A Meaningful Debt Burden
Nov 01We're Not Counting On Lavipharm (ATH:LAVI) To Sustain Its Statutory Profitability
Feb 11Shareholder Returns
| LAVI | GR Pharmaceuticals | GR Market | |
|---|---|---|---|
| 7D | 2.8% | -0.2% | 1.5% |
| 1Y | 21.0% | 2.8% | 42.9% |
Return vs Industry: LAVI exceeded the Greek Pharmaceuticals industry which returned 2.8% over the past year.
Return vs Market: LAVI underperformed the Greek Market which returned 40.1% over the past year.
Price Volatility
| LAVI volatility | |
|---|---|
| LAVI Average Weekly Movement | 3.1% |
| Pharmaceuticals Industry Average Movement | 4.8% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in GR Market | 6.2% |
| 10% least volatile stocks in GR Market | 2.2% |
Stable Share Price: LAVI has not had significant price volatility in the past 3 months compared to the Greek market.
Volatility Over Time: LAVI's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1911 | 282 | Telemaque Lavidas | lavipharm.com |
Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and over the counter (OTC) products, as well as LIFELAB CBD products.
Lavipharm S.A. Fundamentals Summary
| LAVI fundamental statistics | |
|---|---|
| Market cap | €166.16m |
| Earnings (TTM) | €2.07m |
| Revenue (TTM) | €55.11m |
Is LAVI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LAVI income statement (TTM) | |
|---|---|
| Revenue | €55.11m |
| Cost of Revenue | €30.74m |
| Gross Profit | €24.37m |
| Other Expenses | €22.30m |
| Earnings | €2.07m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.012 |
| Gross Margin | 44.22% |
| Net Profit Margin | 3.75% |
| Debt/Equity Ratio | 60.3% |
How did LAVI perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/02 20:04 |
| End of Day Share Price | 2026/01/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lavipharm S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.